dc.contributor.author | Sordi, R | en_US |
dc.contributor.author | Chiazza, F | en_US |
dc.contributor.author | Collotta, D | en_US |
dc.contributor.author | Migliaretti, G | en_US |
dc.contributor.author | Colas, RA | en_US |
dc.contributor.author | Vulliamy, P | en_US |
dc.contributor.author | Brohi, K | en_US |
dc.contributor.author | Dalli, J | en_US |
dc.contributor.author | Collino, M | en_US |
dc.contributor.author | Thiemermann, C | en_US |
dc.date.accessioned | 2019-09-09T10:25:08Z | |
dc.date.available | 2019-05-08 | en_US |
dc.date.issued | 2019-06-07 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/59582 | |
dc.description | This is the accepted manuscript of an article published in Annals of Surgery . The final version is available online: https://doi.org/10.1097/SLA.0000000000003407 | en_US |
dc.description.abstract | OBJECTIVE: To evaluate the potential changes in the plasma levels of resolvin D1 (RvD1) in patients with trauma and hemorrhage. Having found that trauma results in a profound reduction in plasma RvD1 in patients, we have then investigated the effects of RvD1 on the organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat. BACKGROUND: HS is a common cause of death in trauma due to excessive systemic inflammation and multiple organ failure. RvD1 is a member of the resolvin family of pro-resolution mediators. METHODS: Blood samples were drawn from critically injured patients (n = 27, ACITII-prospective observational cohort study) within 2 hours of injury for targeted liquid chromatography tandem mass spectrometry. HS rats (removal of blood to reduce arterial pressure to 30 ± 2 mm Hg, 90 minutes, followed by resuscitation) were treated with RvD1 (0.3 or 1 μg/kg intravenous (i.v.)) or vehicle (n = 7). Parameters of organ injury and dysfunction were determined. RESULTS: Plasma levels of RvD1 (mg/dL) were reduced in patients with trauma+HS (0.17 ± 0.08) when compared with healthy volunteers (0.76 ± 0.25) and trauma patients (0.62 ± 0.20). In rats with HS, RvD1 attenuated the kidney dysfunction, liver injury, and tissue ischemia. RvD1 also reduced activation of the nuclear factor (NF)-κB pathway and reduced the expression of pro-inflammatory proteins such as inducible nitric oxide synthase, tumor necrosis factor-α, interleukin-1β, and interleukin-6. CONCLUSION: Plasma RvD1 is reduced in patients with trauma-HS. In rats with HS, administration of synthetic RvD1 on resuscitation attenuated the multiple organ failure associated with HS by a mechanism that involves inhibition of the activation of NF-κB. | en_US |
dc.description.sponsorship | University of Turin (Ricerca Locale ex-60%). | en_US |
dc.description.sponsorship | People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007–2013) | en_US |
dc.language | eng | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Ann Surg | en_US |
dc.title | Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1097/SLA.0000000000003407 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/31188196 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
qmul.funder | Artesunate in Trauma Haemorrhage - TOP-ART::Wellcome Trust - DoH | en_US |
qmul.funder | Artesunate in Trauma Haemorrhage - TOP-ART::Wellcome Trust - DoH | en_US |
qmul.funder | Artesunate in Trauma Haemorrhage - TOP-ART::Wellcome Trust - DoH | en_US |
qmul.funder | Artesunate in Trauma Haemorrhage - TOP-ART::Wellcome Trust - DoH | en_US |